^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Urothelial Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Pancreatic Cancer)
    New
    Title:

    Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers

    Excerpt:
    AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Clin Oncol
    Title:

    Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations

    Excerpt:
    Here, we present the case reports of two patients with urothelial cancer with BRCA mutations who had clinical responses to PARP inhibition with olaparib.
    DOI:
    10.1200/PO.18.00264